IRD

Opus is a clinical-stage ophthalmic gene-therapy company, not an operating business you can value on the numbers. The $14.2M FY2025 revenue (+29.1%) is essentially RYZUMVI-related partner income, not product sales from the pipeline, so the 21.2x P/S is meaningless — the entire thesis is pipeline optionality. On the fundamentals the picture is poor by design: a -$49.6M net loss, -272% operating margin, -$35.3M operating cash burn, and a -$189M accumulated deficit. Shares outstanding grew 56.4% YoY and total liabilities jumped 208.9%, so existing holders are already being diluted and levered against.

The offsetting story is genuinely credible for a name this size. OPGx-LCA5 has treated six participants with 'clinically meaningful improvements in vision' and no ocular serious adverse events or dose-limiting toxicities, with adult responses durable out to 18 months. It carries RMAT, Rare Pediatric Disease and Orphan Drug designations, completed a constructive Type B RMAT meeting (Nov 6, 2025), and management believes it qualifies for the FDA's new Rare Disease Evidence Principles (RDEP) path — a plausible route to approval on a single-arm, as-few-as-8-patient adaptive study. Dosing is targeted for 2H2026 with topline ~one year later. There is also an active RYZUMVI patent-infringement suit against Sandoz (trial set January 2027) protecting the one commercialized asset.